Current Report Filing (8-k)
May 17 2021 - 4:34PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
May
12, 2021
Date
of report (date of earliest event reported)
MusclePharm
Corporation
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-53166
|
|
77-0664193
|
(State
or other jurisdictions of
incorporation
or organization)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
4500
Park Granada, Suite 202, Calabasas, CA 91302
(Address
of principal executive offices) (Zip Code)
(800)
292-3909
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
N/A
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01
|
Entry
into a Material Definitive Agreement.
|
On
May 12, 2021, MusclePharm Corporation (the “Company”) entered into an Agreement (the “Agreement”) with
Joseph Cannata (“Cannata”), pursuant to which the Company has engaged Cannata on a non-exclusive basis to assist with
the growth of the Company’s energy beverage product line.
In
connection with entry into the Agreement, the Company issued to Cannata an option to purchase 1,673,994 shares of the Company’s
common stock at a price per share of $1.12. The option has an exercise term of 10 years (subject to potential acceleration upon
a sale of the Company) and will vest in two equal tranches upon the achievement of certain net revenue milestones related to the
Company’s energy beverage products.
In
addition, the Company agreed to make quarterly payments to Cannata during the term of the Agreement in amounts equal to 17.5%
of the gross profit attributable to the applicable products, excluding products sold through certain excluded sales channels.
The
Agreement continues in effect unless terminated by the mutual agreement of the parties, upon the sale of the Company and upon
other specified termination events.
Item
7.01.
|
Regulation
FD Disclosure.
|
On
May 13, 2021, the Company issued a press release regarding certain of the matters described in Item 1.01. That press release is
furnished herewith as Exhibit 99.1. The information included in this Current Report on Form 8-K under this Item 7.01 (including
Exhibit 99.1) shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall
be expressly set forth by specific reference in such a filing.
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d) Exhibits
99.1 Press Release, dated May 13, 2021.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
MUSCLEPHARM
CORPORATION
|
By:
|
/s/
Ryan Drexler
|
|
Name:
|
Ryan
Drexler
|
|
Title:
|
Chief Executive Officer
|
Date:
May 17, 2021
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Aug 2023 to Aug 2024